2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 22:35, 22 October 2023
, 22 October 2023→Clinical Trials
| Line 165: | Line 165: | ||
* improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss | * improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss | ||
|- | |- | ||
|Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study {{#pmid:34238308| | |Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study {{#pmid:34238308|pmid34238308}} | ||
|[[RCT]], 6 weeks | |[[RCT]], 6 weeks | ||
* placebo (n=12) | * placebo (n=12) | ||
| Line 179: | Line 179: | ||
* The improvement is muscle, not cardiac, related. | * The improvement is muscle, not cardiac, related. | ||
|- | |- | ||
|The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial {{#pmid:36482258| | |The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial {{#pmid:36482258|pmid36482258}} | ||
|[[RCT]], 8.5 weeks (60 days) | |[[RCT]], 8.5 weeks (60 days) | ||